AA-THEO LA 300 MG
THEOPHYLLINE : 300 MG · DIN 00692700 · AA PHARMA INC
Health Canada status: MARKETED
What is AA-THEO LA?
AA-THEO LA 300 MG contains THEOPHYLLINE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 00692700, held by AA PHARMA INC, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AA-THEO LA used for?
Symptomatic treatment of reversible bronchospasm associated with asthma, chronic bronchitis, emphysema and related bronchospastic disorders in patients 12 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00692700 |
|---|---|
| Brand name | AA-THEO LA |
| Generic / active ingredient | THEOPHYLLINE : 300 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 300 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | R03DA04 THEOPHYLLINE |
| AHFS class | 86:16.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Aug-2019 |
| Original market date | 1993-12-31 00:00:00 |
How is it administered?
Adults: Initial 200-300 mg every 12 hours. Adjust by 50-100 mg every 12 hours at 3-day intervals. Max 16 mg/kg/day. Tablets must be swallowed whole; do not break, chew, or crush.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in provided text (standard storage usually 15-30°C).
How is it supplied?
Bottles of 100 tablets.
Contraindications
Hypersensitivity to theophylline or xanthines; coronary artery disease (where cardiac stimulation is harmful); peptic ulcers; concomitant use with ephedrine in children.
Warnings and precautions
Narrow therapeutic index; monitor serum levels (target 10-20 mcg/mL). Serious toxicity (seizures, arrhythmias) may occur without warning. Caution in cardiac disease, hypertension, or elderly.
What can be used instead?
Other Canadian products sharing ATC code R03DA04 THEOPHYLLINE. 6 of 39 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AA-THEO LA | 100 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 00692689 |
| AA-THEO LA | 200 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 00692697 |
| ELIXIR DE THEOPHYLLINE | 80 MG / 15 ML | ELIXIR | LABORATOIRE ATLAS INC | MARKETED | DIN 00627410 |
| THEO ER | 400 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02360101 |
| THEO ER | 600 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02360128 |
| APO-THEO ER | 400 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | APPROVED | DIN 02358395 |
| APO-THEO ER | 600 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | APPROVED | DIN 02358409 |
| PMS-THEOPHYLLINE ELIXIR | 80 MG / 15 ML | ELIXIR | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 00575151 |
| PULMOPHYLLINE ELX | 80 MG / 15 ML | ELIXIR | LABORATOIRE RIVA INC. | DORMANT | DIN 00466409 |
| QUIBRON T SR TAB 300MG | 300 MG | TABLET (EXTENDED-RELEASE) | BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | CANCELLED POST MARKET | DIN 00556742 |
Who else supplies THEOPHYLLINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. THEOPHYLLINE appears in 1365 registered pack listings across 7 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.